AIMT News and Press, Aimmune Therapeutics Inc. From 09/08/19

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in September: Event: 2019 Wells...

We haven't covered Aimmune Therapeutics, Inc. ( AIMT ) as much as we should, barring an article comparing Aimmune and its distant competitor DBV Technologies ( DBVT ), where we said that AIMT is probably the better investment. Late last year, after DBVT withdrew its US marketing application ...

"The stock market is designed to transfer money from the active to the patient." - Warren Buffet In bioscience investment, it's crucial to filter out opinions from facts. Despite that you hold a fundamentally sound company, you will face streams of negative market opinions. To stay grounde...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy. AR201, an investigational biologica...

Aimmune Therapeutics, Inc. (AIMT) Q2 2019 Earnings Conference Call August 8, 2019 4:30 P.M. ET Company Participants Eric Bjerkholt - Chief Financial Officer Jayson Dallas - President and Chief Executive Officer Dan Adelman - Chief Medical Officer Andrew Oxtoby - Chief Commercia...

Aimmune Therapeutics (NASDAQ: AIMT ): Q2 GAAP EPS of -$1.01 misses by $0.08 . More news on: Aimmune Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

--Webcast and conference call today at 4:30 p.m. ET -- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2019. Operational high...

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Wedbush PacGrow Healthcare Conference on Tuesday, August 1...